Comparison Of First- And Second-Season Palivizumab Prophylaxis In Patients With Congenital Airway Anomalies (Caa) In The Caress Database (2005-2015)

CHD and respiratory syncytial virus: global expert exchange recommendations

“…Recent studies have found that children between 12 and 23 months with certain CHD diagnoses have significantly increased risk of hospitalisation due to respiratory syncytial virus infection compared with children without CHD, 74 and that children younger than 2 years with congenital airway anomalies, without CHD, who received immunoprophylaxis during 1 or 2 respiratory syncytial virus seasons had the same likelihood of respiratory syncytial virus-related hospitalisation in the two virus seasons. 75 Finally, there was general consensus that respiratory syncytial virus immunoprophylaxis needs to be more available in countries with limited resourcesfor example, economic/budget constraints or limited cross-functional support. It was also recognised that there is insufficient evidence to guide its use in subtropical and tropical countries and in patients with certain co-morbidities.…”

“…It should be noted that a full understanding of the risks of severe disease due to respiratory syncytial virus infection in the 2nd year of life continues to evolve. Recent studies have found that children between 12 and 23 months with certain CHD diagnoses have significantly increased risk of hospitalisation due to respiratory syncytial virus infection compared with children without CHD, 74 and that children younger than 2 years with congenital airway anomalies, without CHD, who received immunoprophylaxis during 1 or 2 respiratory syncytial virus seasons had the same likelihood of respiratory syncytial virus-related hospitalisation in the two virus seasons 75 …”